Nascent Biotech, Inc. (NBIO)

OTCMKTS · Delayed Price · Currency is USD
0.0421
-0.0044 (-9.46%)
Sep 25, 2024, 10:15 AM EDT
-73.27%
Market Cap 7.92M
Revenue (ttm) n/a
Net Income (ttm) -1.92M
Shares Out 172.22M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,000
Open 0.0421
Previous Close 0.0465
Day's Range 0.0421 - 0.0421
52-Week Range 0.0306 - 0.2800
Beta -3.27
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2024

About Nascent Biotech

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Na... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Sean Carrick
Country United States
Stock Exchange OTCMKTS
Ticker Symbol NBIO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.